News Sentiment

REPL sentiment intelligence

Replimune Group Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 10.23 Week of 17 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-6.9% over one week, +0.4% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

Replimune stock gains after updated RP1 data and cash runway outlook

Market Reaction

Price moving ahead of tone

57/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -6.9% Price reacting lower
Trend fit Trend active 0.4% over four weeks
Fair value 5.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 40
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 9
Market source 9
Stock Titan 7
Ad-hoc-news.de 4
MT Newswires 4
Investing.com 3
simplywall.st 3
Stocktwits 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 19
Analyst action 7
Regulatory and legal 5
Guidance 2
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
Ad-hoc-news.de Direct company coverage

Replimune stock gains after updated RP1 data and cash runway outlook

Replimune Group Inc. (REPL) stock is reacting to updated clinical data for its oncolytic immunotherapy RP1 and a strengthened cash position. The company reported $357 million in cash and short-term investments as of March 31, 2024, which management expects will fund operations in

Tone
Positive 74/100
Event
Guidance
Published
21 Jul 2026 20:40
Source
Ad-hoc-news.de
TradingView Direct company coverage

ETFs Investing in Replimune Group, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold Replimune Group, Inc. (A2JQN1) stocks, offering investors diversified exposure to the company. The ETFs are sorted by their market value of Replimune holdings and include details such as issuer, management style, e

Tone
Neutral 50/100
Event
Market update
Published
20 Jul 2026 16:10
Source
TradingView
Stock Traders Daily Direct company coverage

Liquidity Mapping Around (REPL) Price Events

This article analyzes Replimune Group Inc. (NASDAQ: REPL) stock, identifying weak near- and mid-term sentiment with a neutral long-term outlook. It highlights an exceptional risk-reward short setup and provides three AI-generated trading strategies tailored for different risk pro

Tone
Negative 26/100
Event
Guidance
Published
15 Jul 2026 17:42
Source
Stock Traders Daily
GlobeNewswire Direct company coverage

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)

Johnson Fistel, PLLP is investigating potential breach of fiduciary duty claims against officers and directors of Replimune Group, Inc. (REPL) on behalf of long-term shareholders who held shares continuously since prior to November 22, 2024. The investigation stems from allegatio

Tone
Negative 13/100
Event
Regulatory and legal
Published
15 Jul 2026 15:11
Source
GlobeNewswire
TradingView Direct company coverage

Price to earnings forward of Replimune Group, Inc. – MUN:7R8

This article provides the "Price to earnings forward" value for Replimune Group, Inc. (MUN:7R8). It indicates that the market is currently closed with no trades. The information is presented on a TradingView page, which also lists various data sources and company information.

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 10:12
Source
TradingView
Stock Titan Direct company coverage

Replimune Group (NASDAQ: REPL) seeks approval to double authorized stock

Replimune Group (NASDAQ: REPL) is seeking stockholder approval to amend its charter to double the authorized common stock from 150,000,000 to 300,000,000 shares. This proposal, requiring 75% approval, is part of three proposals to be voted on at the virtual 2026 annual meeting on

Tone
Neutral 50/100
Event
Regulatory and legal
Published
13 Jul 2026 21:42
Source
Stock Titan
Investing.com Canada Direct company coverage

Form PRE 14A REPLIMUNE GROUP For: 13 July By Investing.com

Investing.com has published a Form PRE 14A for Replimune Group dated July 13. The article provides the filing details, indicates it's from Reuters, and includes the current stock performance for REPL. It also shows a snapshot of various market indices and commodities.

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:31
Source
Investing.com Canada
Quartr Direct company coverage

Replimune Group (REPL) Q4 2026 earnings summary

Replimune Group (REPL) reported its Q4 2026 earnings, highlighting the FDA's acceptance of the BLA resubmission for RP1 in advanced melanoma, with a goal date of August 2, 2026. The company experienced a net loss of $313.9 million for the year while its cash reserves decreased to

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 20:42
Source
Quartr
timothysykes.com Direct company coverage

Replimune Group Inc. (REPL) Stock Price | Live Quotes & Charts | NASDAQ

This NASDAQ page provides live quotes and charts for Replimune Group Inc. (REPL), showing its current stock price and basic performance data. It also includes sections for analyst ratings and earnings information, although specific data for these categories are marked as "N/A" or

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 23:10
Source
timothysykes.com
AD HOC NEWS Direct company coverage

Replimune Group stock and its cancer immunotherapy pipeline

Replimune Group Inc. (REPL) is a Nasdaq-listed biotech company specializing in oncolytic immunotherapies for cancer. Their strategy involves engineering viruses to selectively infect and kill cancer cells, while also stimulating an immune response to "turn cold tumors hot." The c

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 14:10
Source
AD HOC NEWS
MSN Direct company coverage

Replimune says FDA rejected its lead drug for skin cancer

Replimune announced that the FDA has rejected its lead drug for skin cancer. The rejection impacts the company's primary therapeutic candidate and its development pipeline.

Tone
Negative 19/100
Event
Market update
Published
03 Jul 2026 19:09
Source
MSN
Stocktwits Direct company coverage

REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug?

Replimune Group Inc. (REPL) saw its stock drop 19% after the FDA refused approval for its experimental melanoma drug, RP1. The FDA deemed the submitted data "insufficient to conclude substantial evidence of effectiveness" and had previously rejected the initial application in Jul

Tone
Negative 14/100
Event
Regulatory and legal
Published
01 Jul 2026 05:10
Source
Stocktwits
Moomoo Direct company coverage

Press Release: Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

Replimune has released its financial results for the fiscal fourth quarter and year ended March 31, 2026. The report includes key financial figures and a corporate update, offering insights into the company's performance and strategic initiatives for the past year and future outl

Tone
Positive 65/100
Event
Earnings
Published
30 Jun 2026 05:10
Source
Moomoo
Moomoo Direct company coverage

Replimune's Fiscal Q4 Net Loss Narrows

Replimune (NASDAQ: REPL) reported a narrower net loss for its fiscal fourth quarter, coming in at $0.78 per share compared to $0.85 per share in the prior year. The company's total revenue for the quarter was $7.3 million, primarily driven by product sales. Replimune is an oncolo

Tone
Negative 42/100
Event
Earnings
Published
29 Jun 2026 18:41
Source
Moomoo
TradingView Direct company coverage

Replimune Group Inc reports results for the quarter ended March 31 - Earnings Summary

Replimune Group Inc has released its earnings summary for the quarter ended March 31. The report contains financial results for the specified period. Further details are available through the provided source, Refinitiv.

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 12:39
Source
TradingView
Stock Titan Direct company coverage

Replimune (REPL) widens FY 2026 loss as FDA accepts RP1 melanoma BLA

Replimune Group, Inc. (REPL) reported a widened net loss of $313.9 million for fiscal year 2026, compared to $247.3 million in the previous year, with operating expenses reaching $319.9 million. Despite the increased losses and a reduced cash position of $268.9 million (expected

Tone
Neutral 50/100
Event
Balance sheet
Published
29 Jun 2026 12:39
Source
Stock Titan
TradingView Direct company coverage

Replimune Group FY 2026: Revenue $0 Net loss $(313.9)M — 10-K Summary

Replimune Group, Inc. reported a net loss of $(313.94)M for fiscal year 2026, an increase from the $(247.30)M net loss in fiscal 2025, with no reported product revenue. The company is actively investing in research and development for its lead programs RP1, RP2, and RP3, advancin

Tone
Negative 18/100
Event
Earnings
Published
29 Jun 2026 12:39
Source
TradingView
Quantisnow Direct company coverage

Replimune upgraded by Analyst with a new price target

Replimune (REPL) has received a new analyst upgrade, which was promptly alerted to Quantisnow Plus members. The company's stock is being watched by Beagle, a market research tool that provides real-time alerts on news, SEC filings, and other market-moving events. Quantisnow is a

Tone
Neutral 50/100
Event
Analyst action
Published
29 Jun 2026 12:10
Source
Quantisnow
Stock Titan Direct company coverage

Replimune’s melanoma drug review moves toward Aug. 2 FDA decision

Replimune reported its fiscal Q4 and full-year 2026 financial results, with a net loss of $313.9 million, and provided a corporate update. The FDA accepted the BLA resubmission for RP1 + nivolumab in advanced melanoma, setting an August 2, 2026 goal date and an advisory committee

Tone
Positive 71/100
Event
Earnings
Published
29 Jun 2026 11:39
Source
Stock Titan
The Manila Times Direct company coverage

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

Replimune Group, Inc. has announced its financial results for the fiscal fourth quarter and year ended March 31, 2026, alongside a significant corporate update. The FDA has accepted the resubmission of their Biologics License Application (BLA) for RP1 in combination with nivoluma

Tone
Positive 65/100
Event
Earnings
Published
29 Jun 2026 11:39
Source
The Manila Times
The National Law Review Direct company coverage

Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class Action - Contact Levi & Korsinsky

Levi & Korsinsky LLP has issued an investor alert for Replimune Group, Inc. (REPL) shareholders, reminding them about the approaching deadline to join a class action lawsuit. The lawsuit alleges that Replimune made false statements regarding its IGNYTE trial, which resulted in th

Tone
Negative 14/100
Event
Regulatory and legal
Published
28 Jun 2026 15:10
Source
The National Law Review
The Manila Times Direct company coverage

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

Replimune Group, Inc. announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for RP1 in combination with nivolumab for advanced melanoma. The FDA considers this a complete, class 1 response, with a decision expected by August 2, 2026, and

Tone
Positive 71/100
Event
Market update
Published
26 Jun 2026 20:06
Source
The Manila Times
Bitget Direct company coverage

Replimune Group Inc. announced that the U.S. Food and Drug Administration (FDA) has officially accepted its resubmitted Biologics License Application (BLA) for the investigational therapy RP1 for the treatment of advanced melanoma.

Replimune Group Inc. has announced that the U.S. FDA has accepted its resubmitted Biologics License Application (BLA) for the investigational therapy RP1, intended for advanced melanoma treatment. This marks a significant step in the marketing process for their oncolytic virus im

Tone
Positive 71/100
Event
Regulatory and legal
Published
26 Jun 2026 15:10
Source
Bitget
Investing.com Direct company coverage

FDA accepts Replimune’s resubmitted application for RP1

The FDA has accepted Replimune Group, Inc.'s resubmitted Biologics License Application for RP1 in combination with nivolumab for advanced melanoma, classifying it as a complete, class 1 response with a goal date of August 2, 2026. An advisory committee meeting is scheduled for la

Tone
Positive 71/100
Event
Market update
Published
26 Jun 2026 13:09
Source
Investing.com